Cuker, Adam <br/><br/>
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.  [electronic resource] 

 -  Multiple sclerosis (Houndmills, Basingstoke, England)  01 2020 
 - 48-56 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1477-0970 
<br/><br/><label>Standard No.: </label>10.1177/1352458518816612  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Incidence<br/>Interferon beta-1a--administration & dosage<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Purpura, Thrombocytopenic, Idiopathic--drug therapy